There is increasing evidence that an exaggerated accumulation of activated neutrophils is linked to the clinical course of obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease. The present review article focuses on the evidence that the T cell cytokine interleukin (IL)-17 plays a role in orchestrating the accumulation and subsequent activation of neutrophils in the airways and lungs. The mechanistic roles of neutrophils and IL-17 in obstructive airway disease are discussed. It is concluded that targeting IL-17 may consitute a potential strategy for developing novel pharmacotherapeutic interventions against obstructive airway disease.
I NTRODUCTION
There is now increasing evidence that the cytokine interleukin (IL)-17 (also named 'IL-17A') plays a proinflammatory role in the immune system; this evidence has emerged during the 10 years that have passed since the discovery of this intriguing cytokine.
1,2 The first study focusing on the effects of IL-17 protein in the airways 3 has now been followed by several other studies that have improved the understanding of the biology of IL-17 and its potential role in airway inflammation. The present review focuses on the evidence that IL-17 plays a role in orchestrating the accumulation and subsequent activation of neutrophils in the airways and lungs.
A CCUMULATION OF NEUTROPHILS IN AIRWAY AND LUNG DISEASE
The accumulation and activation of neutrophils in the airways and lungs is linked to the course of several inflammatory diseases, including obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and related conditions, such as non-specific bronchial hyperreactivity and chronic bronchitis. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The evidence cited has been obtained through characterization of the number of neutrophils present in airway and lung tissue, in bronchoalveolar lavage (BAL) fluid, in induced sputum and in blood.
A CCUMULATION OF NEUTROPHILS AND FUNCTION OF AIRWAYS AND LUNGS
The number of neutrophils in the airway lumen correlates negatively with non-specific airway reactivity in patients with mild asthma. 19 Interestingly, the number of neutrophils in the airway lumen and mucosa also correlates negatively with lung function in smokers with or without chronic bronchitis or COPD. 10, [15] [16] [17] Among smokers, the number of luminal neutrophils correlates positively with the annual decline in lung function. 20 It is also known that neutrophil recruitment is associated with bronchial hyperresponsiveness in rodent airways in vivo. 21 Thus, it is possible that the accumulation of neutrophils exerts a functional impact on the airways in asthma and COPD.
N EUTROPHILS PRODUCE PATHOGENETICALLY RELEVANT COMPOUNDS
The fact that neutrophils are capable of releasing bioactive compounds that can cause functional alterations in the airways and lungs is interesting because these functional alterations resemble those observed in obstructive airway diseases, such as asthma and COPD.
Neutrophil elastase is an example of a proteolytic enzyme that can be released from neutrophils in the airways. As indicated by its name, elastase degrades elastin, a structural component of the lungs, and it has been shown that the deposition of exogenous elastase in rodent airways leads to emphysema-like alterations in the lungs and tissue remodeling in the airways in vivo. [22] [23] [24] [25] [26] Neutrophil elastase also alters the structure of collagen gels in vitro. 26 Indeed, neutrophil elastase is a potent inducer of secretion by gland cells in rodent airways 27, 28 and it can cause bronchial hyperresponsiveness in murine airways in vivo. 22, 23 In view of these findings, it is of special interest that neutrophil elastase can be detected in obstructive airway disease.
Neutrophil elastase is detected in the submucosa of bronchi of patients with severe asthma, regardless of whether eosinophils are present.
9 Furthermore, even when there is no detectable airway infection present, the luminal concentration of neutrophil elastase is increased in severe asthma. [5] [6] [7] Similarly, an increased luminal concentration of elastase is observed in chronic bronchitis and COPD.
26
There is also evidence consistent with this elastase actually having a functional impact; the luminal concentration of this proteolytic enzyme correlates negatively with lung function in asthma and chronic bronchitis.
6
Certain evidence puts forward some matrix metalloproteases (MMP) as neutrophil-derived compounds contributing to the pathogenesis of obstructive airway disease in the airway and lungs. 30, 31 Thus, the luminal concentration of MMP-8 and -9 is increased in asthma and COPD, respectively. 30, [32] [33] [34] Interestingly, the luminal concentration of MMP-8 correlates negatively with lung function in patients with asthma and MMP-9 appears to mediate allergen-induced airway hyperresponsiveness in sensitized rodents in vivo. 30, 35 In addition to proteolytic enzymes, neutrophils can produce oxygen free radicals and neutrophils from patients with asthma display increased production of these cytotoxic compunds. [36] [37] [38] There is also evidence that oxygen free radicals can induce the transcription of mRNA for neutrophil-recruiting cytokines, such as the neutrophil chemoattractant IL-8, leading to subsequent IL-8 protein release and perpetuation of neutrophil recruitment. 39, 40 Hypotheticallly, these events may contribute to airway remodeling and altered lung function. In line with this, there is evidence that oxygen free radicals contribute to bronchial hyperresponsiveness and that this phenomenon involves neutrophils under certain conditions in mammals in vivo. 22, [41] [42] [43] [44] Furthermore, conditioned medium from human neutrophils can increase the reactivity of human bronchial smooth muscle in vitro , but it remains to be confirmed whether this particular effect is mediated by oxygen free radicals.
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Neutrophils can also perpetuate their own accumulation through the production and release of compunds that, per se , recruit even more neutrophils. These compounds include leukotriene B 4 , tumor necrosis factor (TNF)-α and IL-8.
46-54 Interestingly, there is evidence to support that both TNF-α and IL-8 cause bronchial hyperresponsiveness in rodent airways in vivo . 40, 55, 56 It may be that this TNF-α perpetuates additional neutrophil recruitment via the stimulation of IL-8 in bronchial epithelial cells. 39, 57, 58 The fact that the luminal concentration of IL-8 correlates negatively with bronchial reactivity in patients with mild asthma 19 is, indeed, compatible with neutrophils exerting a functional impact in obstructive airway disease.
To summarize, there is evidence that neutrophils can contribute to gland hypersecretion, bronchoconstriction and bronchial hyperreactivity, as well as tissue destruction in lungs and aiway remodeling in obstructive airway disease. Neutrophils can also perpetuate the additional accumulation of neutrophils at the inflammatory site and this type of local accumulation of neutrophils seems to exert a functional impact on the airways and lungs. For these reasons, the endogenous mechanisms orchestrating the accumulation and activation of neutrophils constitute potential targets for novel pharmacotherapy.
O RCHESTRATION OF NEUTROPHILS IN THE AIRWAYS AND LUNGS
A number of different cell types in the bronchial wall, airway lumen and post-capillary venules can release chemoattractant signals to neutrophils, such as IL-8 and other C-X-C chemokines. Thus, bronchial epithelial cells, bronchial smooth muscle cells, fibroblasts, macrophages/monocytes, neutrophils themselves and even eosinophils have the potential to contribute to neutrophil recruitment by releasing IL-8 in asthma and chronic bronchitis. 39, [57] [58] [59] [60] [61] [62] [63] It remains unknown how these cells are coordinated to orchestrate neutrophil accumulation, in particular because chemokines are believed to function by establishing concentration gradients.
T L YMPHOCYTES AND THE ACCUMULATION OF NEUTROPHILS
There is convincing evidence that certain T lymphocytes orhestrate the recruitment and activation of granulocytes in the airways and lungs, in particular for CD4
+ lymphocytes and eosinophilic granulocytes. Thus, in the airways of patients with newly diagnosed asthma, the total number of lymphocytes, eosinophils and neutrophils is increased.
64 Specific blockade of lymphocytes with an anti-CD4
+ antibody or an anti-IL-2 receptor antibody does prevent allergen-induced recruitment of eosinophils and neutrophils, respectively, in the airways of sensitized rodents in vivo. 65, 66 In addition, in the airways of certain patients with COPD, there is an accumulation of both CD4
+ lymphocytes and neutrophils. 67, 68 Furthermore, exposure to cigarette smoke causes an accumulation of CD4
+ lymphocytes and neutrophils in rodent airways in vivo. 69 The accumulation of CD4 + lymphocytes also relates to functional changes in the airways; the presence of CD4 + lymphocytes is related to bronchial reactivity in the airways of humans and rodents in vivo , even though it is not known whether this phenomenon relates to the orchestration of eosinophils, neutrophils or both. [70] [71] [72] Importantly, the mechanisms linking CD4
+ lymphocytes to the accumulation of neutrophils have remained unclear. This lack of knowledge about mechanisms is in sharp contrast with the vast knowledge about the mechanistic links between CD4 + lymphocytes and eosinophils in the airways and lungs, where Th2 cytokines, such as IL-3, IL-4 and IL-5, as well as the growth factor granulocyte-macrophage colony stimulating factor (GM-CSF), are believed to play important roles.
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P RODUCTION OF IL-17 BY T LYMPHOCYTES
IN VITRO
The homodimer IL-17 is a 155 amino acid molecule with a molecular weight ranging from 15 to 22 kDa.
78
Rodent IL-17 displays a substantial structural homology with human IL-17: the glycosylation site is highly conserved, a fact that is compatible with IL-17 being important for the mammalian immune system.
As judged from studies on spleen or blood cells in vitro, human and rodent CD4
+ lymphocytes can produce, and subsequently release, IL-17 protein when activated in vitro. 2, 78, 79 Of particular interest for inflammatory disease in the airways and lungs, it was recently demonstrated that CD3
+ lymphocytes from rodent lungs can produce free soluble IL-17 protein in vitro. 80 In line with IL-17 being produced by both CD8
+ and CD4 + lymphocytes, memory T lymphocytes (CD45RO) of both these subsets may account for the production of IL-17 protein, as indicated in lymphocytes isolated from the blood of healthy human volunteers and studied in vitro. 81 It has also been claimed that IL-17 is produced mainly by the Th0 and Th1 lymphocyte subsets in vitro, based on findings in synovial CD4
+ cells from patients with rheumatoid arthritis. 82 In one study only, it has been claimed that eosinophils constitute a source of IL-17 protein, but to date there is no published functional evidence that eosinophils can release free soluble IL-17 protein in vitro or in vivo. 83 Taken together, most published evidence favors the idea that, in the airways, IL-17 protein is not released during physiological conditions.
78,84
THE RECEPTOR FOR IL-17
The human receptor for IL-17 displays a unique structure; it is a type I membrane protein containing a 293 amino acid extracellular domain, a 21 amino acid transmembrane domain and a 525 amino acid cytoplasmic tail. 78, 79, [85] [86] [87] The mRNA for the human IL-17 receptor is expressed in a wide range of cells, including airway epithelial cells, foreskin and synovial fibroblasts, B and T lymphocytes and myelomonocytic cells. [85] [86] [87] In line with this, the mRNA for the rodent IL-17A receptor is present in rodent lungs, kidneys, liver and spleen.
85,86
Rodent cells such as fibroblasts, intestinal epithelial cells and various T lymphocyte clones also express mRNA for the rodent IL-17A receptor. 85, 86 Of note, the IL-17 receptor protein appears to be expressed constitutively in several of these human and rodent cells, indicating a general 'readiness' to respond to IL-17 under physiological conditions.
NEUTROPHIL-MOBILIZING FACTORS INCREASED IN AIRWAY EPITHELIAL CELLS BY IL-17
Various human airway epithelial cells respond to stimulation with human IL-17 protein in vitro by producing and releasing the C-X-C chemokine IL-8.
3,88-91 The same is true for the release of the C-X-C chemokines growth-related oncogene (GRO)-α and granulocyte chemotactic protein (GCP)-2. 91, 92 In the case of IL-8 and GRO-α, this chemokine production is probably specific because it is attenuated if the human IL-17 protein is coincubated with an antihuman IL-17 antibody. 3, 92 In terms of gene expression, as well as protein release, human IL-17 protein increases IL-8 and GRO-α to a similar degree as does TNF-α. 92 Interestingly, there are functional data showing that conditioned cell medium from human airway epithelial cells stimulated with human IL-17 protein does cause neutrophil chemotaxis in vitro. 3 It appears as if the major part of this effect is mediated via IL-8, because preincubation of the conditioned medium with an antihuman IL-8 antibody attenuates the chemotactic activity of the cell medium and human IL-17 protein per se does not cause chemotaxis for human blood neutrophils in vitro.
Treatment with a glucocorticoid (hydrocortisone) attenuates the induced release of C-X-C chemokines, such as IL-8, GRO-α and GCP-2, caused by human IL-17 protein in human airway epithelial cells in vitro.
3,89,91
However, there are conflicting data suggesting that the IL-17-induced IL-8 release in human airway epithelial cells, as opposed to TNF-α-induced IL-8 release, is resistant to a glucocorticoid (dexamethasone) under certain conditions. 92 The basis for this discrepancy remains unclear, but it may relate to the fact that, in the specific study mentioned, epithelial cells were cultured in the presence of a glucocorticoid prior to the re-addition of a glucocorticoid.
Interestingly, it appears as if IL-17-induced release of IL-8, but not of GCP-2 or GRO-α, is potentiated by the β 2 -adrenergic receptor agonist salbutamol in human bronchial epithelial cells in vitro. 91 Thus, this observation is compatible with a selective and potentially proinflammatory effect on neutrophil recruitment being caused by a β 2 -adrenergic receptor agonist, but it remains to be confirmed whether this is the basis for a corresponding effect in airways in vivo.
57,93-95
It is not yet certain whether the IL-17-induced release of IL-8 and other C-X-C chemokines in human airway epithelial cells involves a nuclear factor (NF)-κB-inducing kinase, as it does in intestinal epithelial cells in vitro. 96 However, it seems likely that it does, because NF-κB is involved in initiating the transcription of IL-8 in response to a variety of stimuli other than IL-17 in airway epithelial cells, including oxygen free radicals, bacterial products and particulate matter. [97] [98] [99] [100] [101] The role of mitogen-activated protein kinases (MAPK) is more certain; several studies have indicated that these kinases are involved in mediating the intracellular response to IL-17, a response that subsequently leads to the release of C-X-C chemokines in human airway epithelial cells.
89,91,92
Thus, an inhibitor of the MAPK p38 attenuates IL-17-induced release of IL-8 and the same is true for an inhibitor of the MAPK extracellular signal-regulated kinase (ERK) in transformed human airway epithelial cells in vitro, even though only the involvement of ERK has been confirmed in primary human airway epithelial cells in vitro. 89, 90 It is also interesting that IL-17 is capable of interacting with other proinflammatory cytokines when causing the release of C-X-C chemokines. Thus, costimulation of human airway epithelial cells with the Th1 cytokine TNF-α substantially augments the release of C-X-C chemokines, such as IL-8 and GRO-α, compared with stimulation with IL-17 alone. 3, 92 Similarly, costimulation of human airway epithelial cells with the Th1 cytokine interferon (IFN)-γ augments the IL-17-induced release of IL-8 in human airway epithelial cells. 90 Costimulation with the Th2 cytokines IL-4 or IL-13 also augments IL-17-induced IL-8 release in these cells.
90
Human airway epithelial cells also respond to stimulation with human IL-17 by releasing the potentially neutrophil-activating cytokine IL-6 in vitro. 85, [88] [89] [90] 92 Just as for IL-8, the intracellular pathways appear to involve MAPK, even though there are conflicting data on the involvement of the particular MAPK p38, whereas the involvement of ERK has been confirmed in transformed and primary human airway epithelial cells. 88, 89 Again, costimulation with the Th1 cytokine IFN-γ augments the release of IL-6. 90 It remains unknown whether this type of IL-6 release is sensitive to a glucocorticoid or a β 2 -adrenergic receptor agonist.
There is also evidence that IL-17 can stimulate the release of growth factors in human airway epithelial cells under certain conditions. 92, 102 In these epithelial cells, IL-17 releases granulocyte colony stimulating factor (G-CSF) as well as GM-CSF in vitro and the effects of IL-17 on the release of G-CSF and GM-CSF proteins are of a similar order of magnitude as seen with TNF-α.
92,102
Similarly, in terms of gene expression, IL-17 increases G-CSF to a similar degree as does TNF-α. 92 In the case of the release of G-CSF protein, costimulation with TNF-α causes a truly synergistic effect compared with stimulation with IL-17 alone 92 in human airway epithelial cells. This seems to be true for GM-CSF also.
102 Furthermore, there are data suggesting that the effect of IL-17 on GM-CSF protein is functionally relevant in terms of increasing the survival of human neutrophils, at least in vitro.
102
Compared with TNF-α, stimulation with IL-17 alone does not cause any substantial increase in expression of the gene or mRNA for intracellular adhesion molecule (ICAM)-1 in human airway epithelial cells in vitro. 90 Nor does IL-17 increase ICAM-1 protein in these cells. 90 However, costimulation of human airway epithelial cells with human IL-17 plus the Th1 cytokine IFN-γ does cause a marked increase in ICAM-1 protein and the same is true for costimulation with the Th2 cytokines IL-4 and IL-13.
90 At present, there is no published functional evaluation of these in vitro data on ICAM-1.
NEUTROPHIL-MOBILIZING FACTORS INCREASED IN NON-EPITHELIAL CELLS BY IL-17
It is now clear that IL-17 can increase neutrophilmobilizing factors in several non-epithelial stromal cells of potential relevance for inflammation in the airways and lungs. Thus, human venous endothelial cells, cells that constitute a crucial barrier for the extravasation of neutrophils, respond to human IL-17 by releasing IL-8 in vitro and this release is sensitive to a glucuorticoid (hydrocortisone).
3 Primary human lung fibroblasts, cells that possess the potential to communicate with the neutrophil locally in lung tissue, also respond to stimulation with human IL-17 by producing and releasing IL-6 and IL-8 in vitro and the same is true for IL-6 release in embryonic lung fibroblasts. 83 Again, this response to IL-17 appears to be sensitive to a glucocorticoid (dexamethasone). 83 Interestingly, there is now also a preliminary report indicating that human IL-17 stimulates primary human airway smooth muscle cells to release IL-8 in vitro and that this response is not sensitive to a glucccorticoid. 103 At present, there are no studies evaluating the functional significance of these in vitro findings in terms of neutrophil recruitment or activation.
ACCUMULATION OF NEUTROPHILS IN THE AIRWAYS AND LUNGS CAUSED BY IL-17 IN VIVO
Several in vivo studies on rodents have shown that local administration of IL-17 protein from humans and rodents causes a substantial accumulation of neutrophils in the airways. 3, 80, 102, 104, 105 This in vivo response to IL-17 seems to be protein specific, because pretreatment of the IL-17 protein with a neutralizing anti-human IL-17 antibody attenuates its effect.
3 In rodent airways, the effect of IL-17 on neutrophil accumulation is as selective as that of the Th1 cytokine IL-1β. 104 One study indicates that systemic pretreatment with a glucocorticoid (dexamethasone) attenuates the effect of IL-17 on neutrophil accumulation.
3
It has been shown previously that the concentration of the rodent C-X-C chemokine macrophage inflammatory protein (MIP)-2 is increased in the airways after stimulation with IL-17 protein in vivo. 3 In line with this, a neutralizing anti-MIP-2 antibody does attenuate the IL-17-induced accumulation of neutrophils in the airways. 3 There is now also evidence that the IL-17-induced release of IL-6 plays a role similar to that of MIP-2 in the accumulation of neutrophils in rodent airways. 80 In addition, GM-CSF plays a role for the accumulation of neutrophils caused by IL-17 and TNF-α in rodent airways in vivo.
102 It also appears as if endogenous tachykinins, modulated by neutral endopeptidase and acting on NK 1 receptors, facilitate the IL-17-induced accumulation of neutrophils in rodent airways in vivo. 104 There is evidence that IL-17 can activate accumulated neutrophils in the airways in vivo. 105 This effect may be mediated mainly through indirect mechanisms, because local administration of IL-17 protein causes an increase in elastase and myeloperoxidase (MPO) activity in rodent airways in vivo, but no corresponding effect is observed when isolated blood neutrophils from rodents are stimulated by IL-17 protein in vitro. 105 In contrast with IL-17, local administration of IL-1β protein does not increase MPO or elastase activity, even though it does accumulate as many neutrophils in rodent airways in vivo. 105 Of note, although, local administration of rodent IL-1β plus human IL-17 substantially enhances the aforementioned increase in elastase activity, without causing any any pronounced additional increase in neutrophil accumulation.
INTERLEUKIN-17 IN AIRWAY AND LUNG
INFLAMMATION
The evidence for a role for IL-17 in human airway and lung disease is still limited. There is one study showing a substantial increase in free soluble IL-17 protein in the airways of healthy volunteers after exposure to organic dust, in association with a dramatic, local accumulation of neutrophils. 84 Presumably this type of airway inflammation represents the Th1 type.
There is also one study showing a modest increase in free soluble IL-17 protein in the airways of patients with asthma, associated with an increase in immunoreactivity for intracellular IL-17 protein in airway inflammatory cells. 83 It appears feasible that this type of airway inflammation represents the Th2 type. There are no published data yet on putative neutrophil activation associated with the presence of IL-17 protein in human airways.
In addition to the data on human airways, there is now an increasing amount of data on rodent airways in vivo, compatible with IL-17 playing a role in the accumulation of neutrophils in airway disease. Thus, rodents lacking the receptor for IL-17 are more susceptiable to bacterial airway infection caused by Klebsiella pneumonie than are wild-type rodents and this is paralleled by a weakened mobilization of neutrophils in the airways. 106, 107 In line with this, local administration of endotoxin from Escherichia coli requires the presence of endogenous IL-17 protein in order to mobilize neutrophils in the airways. 80 It is also clear that local administration of this endotoxin increases the concentration of IL-17 protein in rodent airways in vivo, compatible with data from another study showing that endotoxin from E. coli increases the mRNA for IL-17 in rodent airways.
80,108
Indeed, all these findings are compatible with IL-17 being involved in airway inflammation of the Th1 type.
Interestingly, two recent studies on rodents in vivo lend further support to an involvement of IL-17 protein in airway inflammation of the Th2 type. One of these studies demonstrates that allergen challenge increases the mRNA for IL-17 in sensitized airways.
109 This study also indicates that endogenous IL-17 protein is required for allergen-induced accumulation of neutrophils and that endogenous IL-17 actually suppresses the local production of IL-5. Finally, a second study suggests that endogenous IL-17 is involved in mediating allergen-induced bronchial hyperreactivity because sensitized rodents lacking the gene for endogenous IL-17 protein display less reactivity to metacholine after allergen challenge than sensitized wild-type rodents.
110
FUTURE RESEARCH ON IL-17
In conclusion, there is substantial evidence that an exaggerated accumulation and activation of neutrophils is linked to the course of obstructive airway disease in humans. There is also evidence of plausible pathogenetic mechanisms involving the neutrophil in acute, severe asthma and COPD. The cytokine IL-17 now emerges as a candidate mediator for a link between the activation of certain T lymphocytes and the accumulation and subsequent activation of neutrophils in airway and lung disease, even though its specific role in obstructive airway disease remains to be determined. Interleukin-17 appears to exert its neutrophil-orchestrating activity indirectly, through stimulation of a number of local cells in the airways and lungs, resulting in the subsequent production and release of a variety of cytokines directly affecting neutrophils. For these reasons, it appears important to document the presence and concentrations of IL-17 in patients with various degrees of obstructive airway disease, in clinically stable patients and in patients with acute exacerbations. Data from these type of studies may reveal whether targeting IL-17 is a plausible strategy for the development of novel pharmacotherapeutic interventions against obstructive airway disease.
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